Zacks Research Has Negative Outlook for BDX FY2025 Earnings

Becton, Dickinson and Company (NYSE:BDX - Free Report) - Zacks Research cut their FY2025 earnings per share (EPS) estimates for Becton, Dickinson and Company in a research note issued to investors on Monday, December 16th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $14.39 per share for the year, down from their prior estimate of $14.43. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company's Q4 2025 earnings at $4.25 EPS, Q2 2026 earnings at $3.83 EPS, Q3 2026 earnings at $4.01 EPS, Q4 2026 earnings at $4.49 EPS and FY2026 earnings at $15.51 EPS.

Several other equities research analysts have also commented on BDX. StockNews.com lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Wednesday. Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, Citigroup raised shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and increased their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Moderate Buy" and an average target price of $283.50.

Becton, Dickinson and Company Stock Performance

BDX traded down $0.26 during trading on Thursday, hitting $223.83. The company's stock had a trading volume of 2,748,846 shares, compared to its average volume of 1,483,629. The business's 50 day simple moving average is $230.06 and its 200-day simple moving average is $233.27. The firm has a market cap of $64.71 billion, a PE ratio of 37.68, a P/E/G ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business's quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.42 EPS.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Wealth Solutions Inc. lifted its position in shares of Becton, Dickinson and Company by 0.5% in the second quarter. Atria Wealth Solutions Inc. now owns 10,963 shares of the medical instruments supplier's stock worth $2,562,000 after buying an additional 59 shares in the last quarter. &PARTNERS boosted its position in shares of Becton, Dickinson and Company by 462.1% during the 2nd quarter. &PARTNERS now owns 16,031 shares of the medical instruments supplier's stock valued at $3,750,000 after acquiring an additional 13,179 shares during the last quarter. Mcrae Capital Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 2.9% in the second quarter. Mcrae Capital Management Inc. now owns 46,262 shares of the medical instruments supplier's stock valued at $10,812,000 after purchasing an additional 1,291 shares in the last quarter. Premier Path Wealth Partners LLC grew its holdings in shares of Becton, Dickinson and Company by 1.8% in the second quarter. Premier Path Wealth Partners LLC now owns 5,154 shares of the medical instruments supplier's stock valued at $1,205,000 after purchasing an additional 91 shares in the last quarter. Finally, Everhart Financial Group Inc. purchased a new stake in Becton, Dickinson and Company during the second quarter valued at $225,000. 86.97% of the stock is currently owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the company's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.